IDT Biologika opens vaccine manufacturing facility in Germany

IDT Biologika built this new vaccine manufacturing facility in 12 months as capacity at its current facilities was nearing zero. (IDT Biologika)

Having hived off its animal health vaccine manufacturing and R&D to France’s Ceva, IDT Biologika is focused entirely on human products. To propel that effort, it has opened a new vaccine manufacturing facility in Germany. 

IDT says the facility in Dessau-Rosslau, which opened this month, not only provides the CDMO with additional capacity but also gives it more flexibility. 

RELATED: NIH grants IDT Biologika 10-year contract for vaccines and biologics manufacturing

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“We are active in markets that not everyone can serve. This is only possible when we are able to react flexibly to those markets’ requirements," CEO Jürgen Betzing said in a statement. "This multifunctional production facility provides the basis for doing so,”

Among the projects that IDT has in hand is a 10-year contract it won last year from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). The $80 million indefinite quantity, indefinite delivery contract requires that IDT stay on call during the contract period as NIAID hammers out the exact content and quantity of each individual project along the way. It also won a contract from global epidemic preparedness group CEPI to work on a vaccine against Middle East respiratory syndrome. 

IDT undertook the expansion project only a year ago as capacity at its current facilities was nearing zero. After completing it in record time, the company is already seeing significant demand for the capacity, IDT said.  

RELATED: IDT Biologika picks up CEPI deal worth up to $36M for MERS vaccine research

“The fact that the building has a utilization rate of close to 50% right from the start underscores our customers’ high demand and the excellent growth perspectives coming with it,” Betzing said.  

IDT earlier this month sold its animal vaccine business to Ceva for an undisclosed amount. While the deal frees IDT to focus on human vaccine work, under the agreement IDT’s Dessau site will continue to manufacture for at least five years the vaccines it sold to Ceva. 

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.